



WEDNESDAY, 13th March 2019 COMMENCING 10:30 AM
AT THE [COPTHORNE HOTEL CARDIFF](#), COPTHORNE WAY,
CULVERHOUSE CROSS, CARDIFF CF5 6DH

AGENDA

Enclosure

1. **Welcome and introduction**

2. **Apologies**

3. **Declarations of interest**

4. **Minutes of previous meeting**

1/AWMSG/0319

To protect commercial confidentiality the following appraisals will be held in private

5. **Appraisal 1: Limited Submission (PAS)**
dasatinib (Sprycel[®]) for the treatment of paediatric patients weighing > 10 kg with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib

2/AWMSG/0319
Appendices

6. **Appraisal 2: Limited Submission (PAS)**
ataluren (Translarna[®]) for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years to 5 years old

3/AWMSG/0319
Appendices

The meeting will now open to the public for the committee decisions

7. **Chairman's report (verbal update)**

8. **Therapeutic Priorities and CEPP Summary 2019-2020**

4/AWMSG/0319

Date of next meeting – Wednesday, 10th April 2019 in Cardiff